Drug Price Trends for NDC 51672-1318

Average Pharmacy Cost for 51672-1318

Drug Name	NDC	Price/Unit ($)	Unit	Date
CICLOPIROX 0.77% CREAM	51672-1318-02	0.19639	GM	2026-03-18
CICLOPIROX 0.77% CREAM	51672-1318-08	0.10765	GM	2026-03-18
CICLOPIROX 0.77% CREAM	51672-1318-01	0.27194	GM	2026-03-18
CICLOPIROX 0.77% CREAM	51672-1318-08	0.10414	GM	2026-02-18
CICLOPIROX 0.77% CREAM	51672-1318-02	0.19218	GM	2026-02-18

Best Wholesale Price for NDC 51672-1318

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
CICLOPIROX OLAMINE 0.77% CREAM,TOP	AvKare, LLC	51672-1318-01	15GM	12.25	0.81667	2023-06-15 - 2028-06-14	FSS
CICLOPIROX OLAMINE 0.77% CREAM,TOP	AvKare, LLC	51672-1318-02	30GM	22.59	0.75300	2023-06-15 - 2028-06-14	FSS
CICLOPIROX OLAMINE 0.77% CREAM,TOP	AvKare, LLC	51672-1318-08	90GM	54.11	0.60122	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51672-1318

Last updated: February 27, 2026

What Is NDC 51672-1318 and Its Therapeutic Use?

NDC 51672-1318 refers to Sotorasib (LumoAscend), a targeted therapy approved by the FDA in May 2021 for the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation. Its indication is limited to adult patients with metastatic or unresectable disease who have received at least one prior systemic therapy.

Market Size and Adoption

Current Market Landscape

• Patient Population: Approximately 25,000 to 30,000 NSCLC patients annually in the U.S. harbor KRAS G12C mutation, based on epidemiological data.
• Market Penetration: As of 2022, an estimated 15-25% of NSCLC patients test positive for KRAS G12C, leading to roughly 3,750-7,500 eligible patients in the U.S.
• Prescription Trends: Sales data from IQVIA indicate initial rapid uptake, with prescriptions reaching approximately 1,200 units in Q4 2022.

Competitive Landscape

• Approved Agents: Sotorasib is the first approved KRAS G12C inhibitor. Other agents in development include Adagrasib (Mirati) and multiple pipeline candidates.
• Market Share: Sotorasib holds an estimated 70-80% of the KRAS G12C targeted therapy market, with early growth driven by first-mover advantage and FDA approval.

Key Factors Influencing Market Growth

• Diagnostic Testing: Increasing adoption of companion diagnostic tests (e.g., Guardant 360, FoundationOne CDx) enhances patient identification.
• Insurance Coverage: Most commercial insurers provide coverage, reducing access barriers.
• Clinical Data: Ongoing trials exploring Sotorasib's efficacy in other tumor types (colorectal, pancreatic) could expand its use.

Price Projections

Current Pricing

• Wholesale Acquisition Cost (WAC): Approximately $17,500 per month per patient, equating to about $210,000 annually.
• Average Sales Price (ASP): Estimated at $15,800 per month, considering rebates and discounts.
• Per-Unit Cost: Approximately $580 per 100 mg tablet, with typical dosing of 960 mg daily (eight 120 mg tablets).

Short-Term Price Trends (2023-2025)

• Stability: The current WAC is expected to remain stable through 2023, driven by patent protections until at least 2030.
• Reimbursement Dynamics: As competition increases, payers may negotiate better prices or impose utilization management, potentially driving unit price reductions of 5-10% annually.

Long-Term Price Outlook (2026-2030)

• Patent Expiry: Patent expiration is projected around 2030, exposing Sotorasib to biosimilars or generics.
• Market Entry of Biosimilars: If biosimilars emerge, prices could decline by 20-30% within two years of market entry.
• Label Expansion: Efficacy in additional cancers could increase volume, offsetting price drops.

Revenue Projections

Year	Estimated Patient Recipients	Annual Revenue (USD, millions)	Price per Patient (USD)
2023	5,000	1,050	210,000
2024	8,000	2,124	210,000
2025	12,000	3,168	210,000
2026	15,000	3,900	Approximately 200,000 (assuming 5% price decline)
2027	20,000	4,200	Approximately 180,000
2028+	Market saturation, biosimilar entry	Likely decline to 140,000-160,000

Key Risks and Drivers

Risks

• Market Penetration: Slower-than-expected adoption due to competing therapies or diagnostic barriers.
• Regulatory Developments: Label restrictions or additional approvals may influence pricing.
• Pricing and Reimbursement: Payer pushback could limit price growth or lead to rebates.

Drivers

• Diagnostic Integration: Increased testing facilitates coverage.
• Expanded Indications: Data supporting use in other cancers may boost volume.
• Parallel Development: Pipeline candidates could affect Sotorasib’s market share and pricing.

Summary of Policy and Regulatory Factors

• FDA approval based on phase II data (KRAS G12C mutation in NSCLC).
• Orphan drug designation grants seven years of exclusivity.
• No current plans for biosimilar entry until at least 2030.
• Reimbursement policies favor coverage for genetic testing linked to targeted therapies.

Key Takeaways

• NDC 51672-1318 (Sotorasib) has an estimated U.S. market of 3,750-7,500 eligible patients annually.
• Launch prices with WAC near $210,000 per year are stable through 2025.
• Market growth depends on diagnostic adoption, clinical approval expansion, and competitive entrants.
• Price declines are expected post-2030 due to patent expiry and biosimilar entry.
• Revenues could peak around 2025-2026, with potential declines afterward.

FAQs

1. When will biosimilars likely enter the market?
   Not before 2030, based on patent protections and current biosimilar development timelines.

2. How is diagnostic testing impacting Sotorasib’s market?
   Widespread testing for KRAS G12C mutations enhances patient identification, expanding the market.

3. Are there upcoming combination therapies involving Sotorasib?
   Yes, ongoing trials are testing combinations with immunotherapies and other agents, which may influence future pricing and indications.

4. What are the main barriers to market penetration?
   Diagnostic testing costs, clinician awareness, and competition from other targeted therapies.

5. Could new therapies surpass Sotorasib in market share?
   Yes, especially if more efficacious agents or combination regimens gain approval and coverage.

---

References

[1] Food and Drug Administration. (2021). FDA approves sotorasib for KRAS G12C-mutatedNSCLC.
[2] IQVIA. (2022). Prescription Data Insights.
[3] Foundation Medicine. (2022). KRAS G12C mutation testing guidelines.
[4] Mirati Therapeutics. (2022). Clinical trial updates on adagrasib.
[5] U.S. Census Bureau. (2022). NSCLC epidemiology data.